Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Huifeng Gao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103800144. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper

Papers 12

  1. SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity in pancreatic cancer. Co-author DOI 10.1186/s13062-024-00513-x↗
  2. M2 macrophage-derived exosomal miR-193b-3p promotes progression and glutamine uptake of pancreatic cancer by targeting TRIM62. Co-author DOI 10.1186/s13062-023-00356-y↗
  3. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Co-author DOI 10.1186/s12863-021-01019-5↗
  4. The Pre-Ablation Circulating Tumor-Associated Inflammatory Index Predicts the Prognosis of Patients with Liver Metastasis from Pancreatic Cancer. Co-author DOI 10.2147/jir.s381807↗
  5. Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ijms231810231↗
  6. Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling. Co-author DOI 10.1186/s13578-020-00457-5↗
  7. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Co-author DOI 10.18632/aging.102638↗
  8. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis Co-author DOI 10.21203/rs.2.24244/v1↗
  9. miR-939-5p Contributes to the Migration and Invasion of Pancreatic Cancer by Targeting ARHGAP4. Co-author DOI 10.2147/ott.s227644↗
  10. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Co-author DOI 10.1155/2018/7343090↗
  11. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Last author DOI 10.1159/000348530↗
  12. shRNA-mediated Slc38a1 silencing inhibits migration, but not invasiveness of human pancreatic cancer cells. Co-author DOI 10.3978/j.issn.1000-9604.2013.09.03↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lianyu Chen · 6 shared papers, 2018–2022 · strength 0.79
  2. Linjia Peng · 3 shared papers, 2022–2023 · strength 0.59
  3. Zhen Chen · 6 shared papers, 2013–2022 · strength 0.55
  4. Yujie Li · 3 shared papers, 2022 · strength 0.54
  5. Yehua Shen · 3 shared papers, 2013–2024 · strength 0.42
  6. Zhiqiang Meng · 5 shared papers, 2013–2020 · strength 0.40
  7. Gang Chen · 2 shared papers, 2020–2024 · strength 0.38
  8. Hao Chen · 2 shared papers, 2022 · strength 0.37
  9. Luming Liu · 3 shared papers, 2013–2023 · strength 0.33
  10. Chien‐shan Cheng · 3 shared papers, 2018–2020 · strength 0.32
  11. Hao Chen · 3 shared papers, 2018–2020 · strength 0.31
  12. Shu Dong · 2 shared papers, 2020–2022 · strength 0.28
  13. Changjing Huang · 1 shared paper, 2024 · strength 0.26
  14. Liming Zhu · 1 shared paper, 2024 · strength 0.26
  15. Ye Li · 2 shared papers, 2020 · strength 0.24
  16. Ke Zhang · 1 shared paper, 2023 · strength 0.22
  17. Hao Hui Chen · 1 shared paper, 2023 · strength 0.22
  18. Yong Wu · 1 shared paper, 2022 · strength 0.19
  19. Hao Chen · 1 shared paper, 2022 · strength 0.16
  20. Panling Xu · 1 shared paper, 2022 · strength 0.16
  21. Ke Zhang · 1 shared paper, 2022 · strength 0.16
  22. Jiangang Zhao · 1 shared paper, 2020 · strength 0.13
  23. Ye Li · 1 shared paper, 2020 · strength 0.13
  24. Luming Liu · 1 shared paper, 2020 · strength 0.13
  25. Liping Zhuang · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.